NEO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
NEO is not a strong buy right now for a beginner long-term investor, even with $50,000-$100,000 to deploy. The pre-market tone is mildly positive and analyst sentiment has improved, but the stock is extended technically and there is no confirmed Intellectia buy signal. My direct view: hold off on buying today and wait for a better entry after momentum cools or price pulls back closer to support.
NEO is in a short-term bullish phase, but the setup is stretched. MACD histogram is positive and expanding, which supports upside momentum. However, RSI_6 at 88.064 is deeply overbought, suggesting the move is already extended. Moving averages are converging, indicating the trend is not yet a clean, mature uptrend. Price is trading near 10.19 pre-market, above pivot 9.148 and close to resistance at 9.948 with the next resistance at 10.441. That means upside is possible, but the current level is not an attractive low-risk long-term entry for an impatient buyer.
Recent analyst action is constructive. Leerink upgraded the stock to Outperform with a $25 target, Benchmark raised it to Buy with an $11 target, and TD Cowen lifted its target to $14 while maintaining Buy. The company also reported a modest beat and raise in 1Q, including 23% NGS growth, with expectations for margin improvement in the second half from new high-value NGS and MRD products. The stock trend model also suggests a positive next-day, next-week, and next-month bias.
There was no news in the recent week, so there is no fresh event-driven catalyst beyond earnings and analyst reactions. BofA cut its target to $11 and kept a Neutral rating, which shows the Street is not fully aligned. RSI is extremely overbought, so the stock may already be extended after the recent run. Hedge funds and insiders are both neutral, with no significant buying trend. No recent congress or politician trading data was available.
Latest quarter season: 1Q 2026. Financial commentary from analysts says the company delivered a modest beat and raise, with better-than-expected revenue and in-line earnings, plus 23% NGS growth. Guidance commentary points to improving adjusted EBITDA in the second half as margins expand from the launch of new, high-value NGS products and MRD testing. I could not verify a full financial snapshot because the provided data returned an error, so the assessment is based on the available quarter commentary.
Analyst sentiment is mixed but improving overall. Positive moves include Leerink upgrading to Outperform with a $25 target, Benchmark upgrading to Buy with an $11 target, and TD Cowen raising its target to $14 and keeping Buy. On the cautious side, BofA cut its target to $11 and stayed Neutral. Net view from Wall Street is cautiously bullish: the pros like the improving execution, NGS growth, and EBITDA trajectory, but some still think the story is not yet compelling enough to justify a decisive buy at current levels.
